Business Development & Licensing

A partnership with Servier means working closely with dedicated experts capable of implementing and developing alliances in over 90 countries.

A long-term and personalized relationship

The scope and complexity of science today require an open and cooperative network between all stakeholders in research. This is why we are always actively searching for research partnerships, with academic organizations as well as other pharmaceutical groups and biotechnology companies. Choosing a partnership with us means long-term investment, via our foundation-based structure. It means choosing scientific and medical excellence with our top scientists and extensive clinical expert network. Each partnership is unique, and creates a personalized relationship.

What we can offer you

A long-term and personalized relationship.
Proven track record in clinical development, including large-scale outcome studies
Strong network of contacts and an excellent reputation with top experts in the pharmaceutical sector.
Considerable R&D capabilities, including 1 900 exclusively dedicated staff in France and 16 International Centres for Therapeutic Research.
High level of commitment and scientific expertise.
Partnerships managed by dedicated teams of alliance professionals certified by ASAP.
Presence or commercial activity in more than 90 countries.

What we are looking for in business development

We are seeking opportunities in our 5 areas of research and development:

We are interested in all innovative “best-in-class” products, from the target stage to late-stage clinical trials, provided they bring true therapeutic innovation to areas of unmet needs.
We are also interested in licensing marketed, or near-market, products that complement our existing portfolio.
Out-licensing: We are looking for partners in the United States and Japan to license some of our drug candidates and medicinal products, and global partners for non-strategic products.
What types of agreements? - Global rights with or without the United States and Japan - Local and regional agreements - R&D collaborations starting immediatly or after option exercise
  • Arrhythmia-induced cardiomyopathy
  • Heart failure (acute and chronic)
  • Atrial fibrillation
  • Ischemic cardiomyopathy
  • Lipid disorders
  • Hypertension
  • Stroke (cerebrovascular accidents – CVA)
  • Venous disease

Solid tumors & hematologic cancers:

  • Apoptosis: focus on the resistance of cancer cells to programmed death
  • Immunotherapy: mobilization of T-cells against tumors with allogeneic CAR-T cells
  • Protein-protein interactions: new high-potential targets

Drug candidates:

  • That demonstrate signs of clinical activity
  • Preferably against malignant gastrointestinal and hematological tumors

<ul class=”blue-list”>
<li>Type 1 and type 2 diabetes</li>
<li>Diabetic kidney disease (DKD)</li>
<li>Non-alcoholic steatohepatitis (NASH) and metabolic syndrome</li>
<li>Diabetic retinopathy</li>
Any innovative product in late-stage clinical trials demonstrating promising value to diabetic patients.

In research phase:

  • Alzheimer disease
  • Parkinson disease
  • Diseases that specifically modify beta-amyloid, TAU and alpha-synuclein proteins

In development phase:

  • Neurology:
    • Alzheimer disease
    • Parkinson disease
    • Multiple sclerosis
    • Neurovascular disorders
    • Other: Cerebral trauma, amyotrophic lateral sclerosis (ALS), Huntington disease, neuropathic pain
  • Psychiatry:
    • Autism
    • Schizophrenia

In research phase:

  • Modulation of immune effector cells activation with specific focus on T cells and B cells

In development phase:

  • Immune-inflammatory and autoimmune diseases with a focus on Lupus, primary Sjögren’s syndrome, and systemic sclerosis
  • Interest in other indications in this field, especially involving an unmet therapeutic need and/or similar pathophysiological mechanism
  • Targeted molecules whose therapeutic approach is supported by biomarkers and/or a mode of action



We currently have more than 50 active alliances with biotech and pharmaceutical companies across all our areas of activity:

If you wish to submit a project, please fill out the following form.




Each year, our teams take part in around 40 international scientific conferences. If you would like to meet us, talk with us, or propose a project, here is a list of the main partnering events for 2018:

12 March
BIO Europe Spring Conference Amsterdam (The Netherlands)
19 March
BIO Asia International Conference Tokyo (Japan)
25 April
ChinaBio Partnering Forum Suzhou (China)
4 June
BIO International Convention Boston (USA)
18 Sept
BIO Latin America Rio de Janeiro (Brasil)
See more